Divi's Laboratories (DIVISLAB) — Financial Results

Divi's Laboratories reported Q2 FY2026 consolidated revenue of ₹2,860 crores (up 17% YoY) with profit after tax of ₹689 crores (up 35.1% YoY). H1 FY2026 total income reached ₹5,389 crores with PAT of ₹1,234 crores. The company promoted Nimmagadda Venkata Anirudh to President (Nutraceuticals) effective November 7, 2025. Balance sheet strength remains solid with total assets of ₹18,151 crores and equity of ₹15,369 crores. Auditors issued unmodified review reports confirming compliance with Indian Accounting Standards.

📄 View Original Announcement (PDF)

📊 Stock Analysis — DIVISLAB ✨ Ask AI About This

About Divi's Laboratories Limited (DIVISLAB)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,79,470.03 Cr P/E: 72.4 ROE: 16.6% ROCE: 22.1%

View full DIVISLAB stock details →

📡 Get AI alerts when DIVISLAB files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track DIVISLAB — Free

💡 Ask AI about this filing

"How does this financial results affect Divi's Laboratories Limited's outlook?" "What did Divi's Laboratories Limited announce on 7 November 2025?" "Is this positive or negative for DIVISLAB?"

Ask AI Free →

📊 More DIVISLAB filings

See all DIVISLAB filings →

🔥 Also filed on 7 November 2025

TRENT Trent Limited Financial Results TRENT Trent Limited Financial Results TORNTPHARM Torrent Pharmaceuticals Limited Financial Results TORNTPHARM Torrent Pharmaceuticals Limited Financial Results TORNTPHARM Torrent Pharmaceuticals Limited Financial Results ZYDUSLIFE Zydus Lifesciences Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when DIVISLAB files new disclosures

Track DIVISLAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.